Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company’s pipeline includes tobevibart, a neutralizing monoclonal antibody targeting hepatitis delta virus, and elebsiran, a small interfering RNA, which are being evaluated in combination for chronic hepatitis delta. In oncology, the company advances dual-masked T-cell engagers including VIR-5500, VIR-5818, and VIR-5525 for various solid tumors. Vir Biotechnology also develops broadly neutralizing antibodies for HIV cure and preclinical candidates for influenza and coronavirus. Its R&D is driven by the proprietary dAIsY AI platform for antibody optimization and the PRO-XTEN masking technology, in-licensed from Sanofi. Partnerships include Norgine for commercial rights in Europe, Australia, and New Zealand, and Brii Bioscience for rights in the Greater China Territory. The company was founded in 2014.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage vir.bio
Sector Healthcare IR page investors.vir.bio/overview/default.aspx
Tags
antibody discovery, t-cell engagers, hepatitis delta, hiv cure, oncology, infectious diseases, ai drug discovery, protein engineering, sirna, monoclonal antibodies, tobevibart, elebsiran, VIR-5500, VIR-5818, VIR-5525, dAIsY, PRO-XTEN, Xtend, Norgine, Brii Bioscience, Sanofi, Amunix Pharmaceuticals, Xencor
Press page —

Metrics

Valuation  
Market cap $ 1.88B
Market cap (USD) $ 1.88B
P/E -8.81
PEG —
P/BV 2.10
P/S 6.21
P/OCF -13.34
P/FCF -13.26
Dividend yield —
Turnover / mcap —
Returns  
ROE -45.7%
ROI -70.4%
ROIC -57.8%
Profit margin -638.9%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 50
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 68.556M 74.205M 86.18M 1.616B 1.095B 76.368M 8.091M 10.668M
Net profit -437.987M -521.96M -615.117M 515.837M 528.584M -298.665M -174.683M -115.884M
Free cash flow -396.613M -453.653M -800.358M 1.595B -69.406M -197.49M -138.572M -102.288M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 6.03 7.34 10.06 25.31 41.87 26.78 12.58 —
Price performance 12m -0.18 -0.27 -0.6 -0.4 0.56 1.13 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 773M 0.00 — — —
↳ YoY growth -100.0%
Lease liabilities (USD) — — — 1.1M 71.1M 137M 128M 125M 97.9M 97.9M
Cash and deposits (USD) 14.1M 189M 47.6M 109M 437M 348M 849M 242M 223M 232M
Intangible assets (USD) — — 36.9M 35.7M 33.8M 33.3M 32.8M 22.6M 8.12M 7.85M
Right-of-use assets (USD) — — — — 61.9M 87.2M 82.6M 71.2M 59.7M 62.1M
Cash flow detail
Operating cash flow (USD) — -66.4M -94.1M -130M -191M -47.6M 1.66B -779M -446M -392M
Purchases of property, plant and equipment (USD) — -2.74M -8.19M -8.94M -6.55M -21.8M -68M -21.6M -7.3M -4.83M
Change in receivables (cash effect) (USD) — — — — 0.00 -773M 770M -565,000 -6.51M —
Change in payables (cash effect) (USD) — 2.01M 1.47M 964,000 -790,000 -171,000 797,000 732,000 -988,000 5M
Income taxes paid (cash effect) (USD) — — — — 0.00 0.00 -252M -2.68M -786,000 -2.42M
Share-based compensation (USD) — 4.78M 5.05M 8.72M 27.6M 83.8M 102M 111M 78.5M 49.1M
Operating cash flow before change in receivables (USD) — — — — -191M 725M 893M -778M -440M —
Free cash flow (OCF - PPE - intangibles) (USD) — -69.1M -102M -139M -197M -69.4M 1.6B -800M -454M -397M
Income detail
Research and development expense (USD) — 62.5M 100M 148M 302M 448M 475M 590M 506M 456M
↳ 5y CAGR +50.0% +42.5% +27.8% +8.6%
Total comprehensive income (USD) — -69.9M -116M -175M -299M 529M 508M -607M -523M -438M
Comprehensive income to owners (USD) — -69.9M -116M -175M -299M 529M 508M -607M -523M -438M
Reported Mar 26, 2020 Mar 26, 2020 Mar 26, 2020 Mar 26, 2020 Feb 28, 2023 Feb 28, 2023 Feb 28, 2023 Feb 26, 2024 Feb 27, 2025 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Vir Biotechnology Announces Proposed Public Offering Bull 0 Bear 4 Financing

SAN FRANCISCO, November 12, 2026 – Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock to be sold in the offering at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be offered by Vir Biotechnology. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers for the offering. Raymond James is acting as co-manager for the offering.

The shares described above are being offered pursuant to a registration statement that was filed with the U.S.

Vir Biotechnology, Inc. — Regulation FD Disclosure Bull 6 Bear 0 Clinical/regulatory

Vir Biotechnology, Inc. (the Company) is holding a virtual investor conference call at 5:30 a.m. PT / 8:30 a.m. ET on November 9, 2026, to discuss the topline results from the pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly subcutaneous administration of the combination regimen of elebsiran, an investigational small interfering RNA (siRNA), and tobevibart, an investigational monoclonal antibody, in adults with chronic hepatitis delta (CHD) (such results, the ECLIPSE 1 TLR), as well as expanded data and an exploratory analysis from the Phase 2 SOLSTICE study evaluating the combination regimen and tobevibart monotherapy in adults with CHD (such data and analysis, the SOLSTICE Update). A live webcast of the virtual investor event will be made available on https://investors.vir.bio and will be archived there for 30 days.

Other Events

ECLIPSE 1 TLR Certain data from the ongoing Phase 3 ECLIPSE 1 clinical trial, including the ECLIPSE 1 TLR, were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, in Denver, Colorado on November 8, 2026.

11/05/2026

Download(opens in new window)PDF 218 KB

- Conference call to discuss topline ECLIPSE 1 results and expanded Phase 2 SOLSTICE data scheduled for November 9, 2026, at 8:30 a.m. ET / 5:30 a.m. PT

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026.

  • **Primary endpoint results of ECLIPSE 1: A randomized open-label Phase 3 study evaluating efficacy and safety of elebsiran and tobevibart for chronic hepatitis delta
    **Format: Oral presentation
    Session: Late Breaking Abstract Parallel Session 1
    Presenter: Nancy Reau
    Date: November 8, 2026
    Time: 2:15 p.m. to 2:30 p.m. MT

In addition to the ECLIPSE 1 late-breaking oral presentation, the Company will present two previously announced oral presentations featuring expanded Phase 2 SOLSTICE data.

  • **Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV RNA responses through Week 96
    **Format: Oral presentation
    Session: Hepatitis – Other Infections
    Presenter: Tarik Asselah
    Date: November 8, 2026
    Time: 2:45 p.m. to 3:00 p.m. MT

  • From inflammation to surveillance: Intrahepatic NK cell remodelling with elebsiran and tobevibart in chronic hepatitis D - A translational sub-study of the SOLSTICE trial
    Format: Oral presentation
    Session: Inflammation and Immunobiology
    Presenter: Upkar Gill
    Date: November 7, 2026
    Time: 5:45 p.m. to 6:00 p.m. MT

Conference Call

Vir Biotechnology will host a conference call to discuss the ECLIPSE 1 topline results and expanded SOLSTICE data at 8:30 a.m. ET / 5:30 a.m. PT on Monday, November 9. A live webcast will be available at https://investors.vir.bio and will be archived for 30 days.

About the ECLIPSE Registrational Program

ECLIPSE is a registrational program to evaluate the efficacy and safety of the elebsiran and tobevibart regimen in patients with chronic hepatitis delta (CHD). ECLIPSE includes three randomized, controlled trials designed to evaluate the regimen in comparison to deferred treatment or bulevirtide. ECLIPSE 1 (NCT06903338 ) evaluates the efficacy and safety of the regimen compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited. ECLIPSE 2 (NCT07128550 ) evaluates the efficacy and safety of switching to the regimen in people with CHD who have not achieved viral suppression with bulevirtide therapy. ECLIPSE 3 (NCT07142811 ) evaluates the regimen compared to bulevirtide in bulevirtide-naïve patients, and it is designed to provide important data to help establish access and reimbursement in key markets. ECLIPSE 1, 2 and 3 are pivotal trials designed to generate a comprehensive data package in support of potential submission to global regulatory agencies.

About Elebsiran and Tobevibart

Elebsiran and tobevibart are investigational agents being evaluated as a novel combination regimen administered monthly as two separate sequential subcutaneous injections for the treatment of chronic hepatitis delta (CHD). The combination is designed to disrupt the hepatitis delta virus (HDV) life cycle at multiple points by addressing both viral entry and the sustained presence of hepatitis B surface antigen (HBsAg) that enables ongoing HDV replication.

Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of HBsAg.

Tobevibart is an investigational broadly neutralizing monoclonal antibody (mAb) targeting HBsAg. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology’s proprietary mAb discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor’s Xtend™ technology to extend half-life.

About Chronic Hepatitis Delta (CHD)

CHD is the most severe form of chronic viral hepatitis1 and was recently classified as carcinogenic by the International Agency for Research on Cancer.2 People living with the disease rapidly progress to cirrhosis, liver failure3 and liver-related death.1 Because ongoing hepatitis delta virus (HDV) replication drives disease progression, achieving undetectable virus, as defined by HDV RNA TND (target not detected), is considered an important virologic marker associated with improved clinical outcomes in CHD.4 Individuals with CHD who have detectable HDV RNA are at a higher risk of experiencing any liver-related event, including developing compensated and decompensated cirrhosis, hepatocellular carcinoma, liver transplantation and mortality, compared to patients with undetectable HDV RNA.4 There are currently limited approved treatments in the U.S. and globally.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Media Contact
Caren Scannell
Director, Communications
[email protected]

Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
[email protected]

Source: Vir Biotechnology, Inc.

View all news

Quick Links

IR Contact

Vir Biotechnology, Inc.
1800 Owens St., Suite 900
San Francisco, CA 94158

contact us by phone at 415-906-4324

[email protected]

Follow us

Investor Email Alerts

To opt in for investor email alerts, please enter your email address in the field and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Vir Biotechnology, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section. If you experience any issues with this process, please contact us for further assistance.

By providing your email address, you are providing consent to Vir Biotechnology to send you the requested Investor Email Alert updates.

* Required

Subscribe to email alertsEmail Address *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
Quarterly Results
Annual Reports
SEC Filings

Submit Sign Up

Email Alert Sign Up Confirmation

REQUEST A MEETING WITH MANAGEMENT >

© 2026 Vir Biotechnology, IncTM - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

(opens in new window)

Company Logo

This website uses cookies (including other similar technologies) to optimise and improve the experience on our website. Some cookies are strictly necessary, as without these the website could not operate. For other types of cookies, we require your permission. Please confirm your choices in relation to these other types of cookies. For more information, please see ourCookie Policy.

  • Functional Cookies
Functional Cookies
------------------
  • Strictly Necessary Cookies
Strictly Necessary Cookies
--------------------------
  • Performance Cookies
Performance Cookies
-------------------
  • Targeting Cookies
Targeting Cookies
-----------------

Cookies Settings

Save Choices

Reject All CookiesAccept All Cookies

Powered by Onetrust

Company Logo

Cookie Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. A cookie is a small piece of data (text file) that a website, when visited by a user, asks your browser to store on your device in order to remember information about you. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. These cookies are listed in the table below as ‘Strictly Necessary Cookies’. For all other types of cookies, we need your permission. Because we respect your right to privacy, you have different options: 1) Reject all the optional cookies (by clicking ‘Reject All’), 2) Select which optional cookies you want used (by clicking on the cookies you want to allow and then clicking ‘Confirm My Choices’), or 3) Allow all the optional cookies (by clicking 'Allow all’). Please note, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More Information on Cookie Notices and Cookie Consent

Allow All

Manage Consent Preferences

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Confirm My Choices

Powered by Onetrust

Prompts

Vir Biotechnology, Inc. (ticker VIR), listed in United States.

ETFs Holding Vir Biotechnology, Inc.

ETF Weight in ETF Shares Market value As of
WCEO 0.17% 1,950 $ 16.887K Jul 31, 2026
JMEE 0.15% 461,138 $ 4.266M Nov 17, 2026
FSEV 0.10% 670 $ 6,827.30 Jun 30, 2026
AVSC 0.10% 321,562 $ 3.081M Nov 16, 2026
VFMO 0.08% 141,580 $ 1.549M Aug 31, 2026
FESM 0.07% 413,818 $ 4.217M Jun 30, 2026
RESM 0.04% 156 $ 1,589.64 Jun 30, 2026
DFAS 0.04% 1,162,644 $ 14.091M Nov 12, 2026
SMDX 0.03% 3,866 $ 37.036K Nov 17, 2026
DXUV 0.02% 78,332 $ 949.384K Nov 12, 2026
DFAC 0.01% 670,875 $ 8.131M Nov 12, 2026
DFAT 0.01% 217,280 $ 2.633M Nov 12, 2026
DFSU 0.00% 9,821 $ 119.031K Nov 12, 2026
DCOR 0.00% 170,724 $ 2.069M Nov 12, 2026
DFAU 0.00% 45,037 $ 545.848K Nov 12, 2026
DFSV 0.00% 93,502 $ 1.133M Nov 12, 2026
DFUS 0.00% 43,396 $ 525.96K Nov 12, 2026
AVUS 0.00% 34,490 $ 330.414K Nov 16, 2026